Infigratinib Demonstrates Clinical Activity Across Settings in Urothelial Cancer
https://www.onclive.com/view/infigratinib-demonstrates-clinical-activity-across-settings-in-urothelial-cancer
https://www.onclive.com/view/infigratinib-demonstrates-clinical-activity-across-settings-in-urothelial-cancer
May 31st, 2020
Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC
https://www.onclive.com/view/alectinib-continues-to-maintain-significant-os-benefit-in-emalkem-nsclc
https://www.onclive.com/view/alectinib-continues-to-maintain-significant-os-benefit-in-emalkem-nsclc
May 30th, 2020
Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC
https://www.onclive.com/view/tepotinib-displays-durable-clinical-benefit-in-metex14altered-nsclc
https://www.onclive.com/view/tepotinib-displays-durable-clinical-benefit-in-metex14altered-nsclc
May 30th, 2020
Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review
https://www.onclive.com/view/pralsetinib-active-across-emretem-tumor-types-and-gains-fda-review-
https://www.onclive.com/view/pralsetinib-active-across-emretem-tumor-types-and-gains-fda-review-
May 31st, 2020
Dr. Plimack on Updated Findings of the KEYNOTE-426 Study in RCC
https://www.onclive.com/view/dr-plimack-on-updated-findings-of-the-keynote426-study-in-rcc
https://www.onclive.com/view/dr-plimack-on-updated-findings-of-the-keynote426-study-in-rcc
May 31st, 2020
MGD013 Demonstrates Encouraging Activity Across Tumor Types
https://www.onclive.com/view/mgd013-demonstrates-encouraging-activity-across-tumor-types
https://www.onclive.com/view/mgd013-demonstrates-encouraging-activity-across-tumor-types
May 31st, 2020
TRK Inhibitor Continues to Show Multi-Cancer Effects
https://www.medpagetoday.com/meetingcoverage/asco/86834
https://www.medpagetoday.com/meetingcoverage/asco/86834
Jun 1st, 2020
Early Palliation: Boon for AML Patients on Intensive Chemo
https://www.medpagetoday.com/meetingcoverage/asco/86820
https://www.medpagetoday.com/meetingcoverage/asco/86820
Jun 1st, 2020
Autologous TILs Active in Refractory Melanoma
https://www.medpagetoday.com/meetingcoverage/asco/86840
https://www.medpagetoday.com/meetingcoverage/asco/86840
Jun 1st, 2020
Hydroxychloroquine, Azithromycin Combo Risky for Cancer Patients
https://www.medpagetoday.com/meetingcoverage/ascovideopearls/87062
https://www.medpagetoday.com/meetingcoverage/ascovideopearls/87062
Jun 14th, 2020
Newly Diagnosed MM: RVd Still Standard of Care
https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/87038
https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/87038
Jun 11th, 2020
High Marks for CAR T Cells in R/R Myeloma
https://www.medpagetoday.com/meetingcoverage/asco/86858
https://www.medpagetoday.com/meetingcoverage/asco/86858
Jun 2nd, 2020
Second Surgery Gets OS Win in Recurrent Ovarian Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86836
https://www.medpagetoday.com/meetingcoverage/asco/86836
Jun 1st, 2020
Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer
https://www.onclive.com/view/dr-gwin-on-the-mechanism-of-action-of-alphatea-in-her2positive-metastatic-breast-cancer
https://www.onclive.com/view/dr-gwin-on-the-mechanism-of-action-of-alphatea-in-her2positive-metastatic-breast-cancer
Jun 4th, 2020
Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm
https://www.onclive.com/view/dr-mascarenhas-on-the-impact-of-ruxolitinib-on-the-myelofibrosis-treatment-paradigm
https://www.onclive.com/view/dr-mascarenhas-on-the-impact-of-ruxolitinib-on-the-myelofibrosis-treatment-paradigm
Jun 4th, 2020
Surgery for Metastatic Breast Cancer Fails to Boost Overall Survival
https://www.medpagetoday.com/meetingcoverage/asco/86802
https://www.medpagetoday.com/meetingcoverage/asco/86802
May 31st, 2020
Pembrolizumab May Help in Triple-Negative Breast Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86804
https://www.medpagetoday.com/meetingcoverage/asco/86804
May 31st, 2020
PTSD Symptoms Common in Stem Cell Recipients
https://www.medpagetoday.com/meetingcoverage/asco/86811
https://www.medpagetoday.com/meetingcoverage/asco/86811
May 31st, 2020
